前沿生物跌4.4% 2020年上市见顶两募资共20.44亿

Group 1 - The stock of Frontline Bio (688221.SH) closed at 18.25 yuan, with a decline of 4.4%, currently in a state of breaking issue [1] - Frontline Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total share capital after issuance, at a price of 20.50 yuan per share [1][2] - The total amount raised from the issuance was 184.418 million yuan, with a net amount of 171.729 million yuan, intended for various clinical research projects and working capital [2][4] Group 2 - The highest stock price of Frontline Bio on the listing day was 35.53 yuan, marking the peak since its listing [2] - The underwriting and sponsorship fees for the initial public offering amounted to 12.689 million yuan, with the underwriting and sponsorship fee being 11.613 million yuan [2] - The actual controller of Frontline Bio is Dong Xie, who holds U.S. nationality and has permanent residency in China [3]